Literature DB >> 31593597

Guidance for Studies Evaluating the Accuracy of Sputum-Based Tests to Diagnose Tuberculosis.

Samuel G Schumacher1, William A Wells2, Mark P Nicol3, Karen R Steingart4, Grant Theron5, Susan E Dorman6, Madhukar Pai7, Gavin Churchyard8,9,10, Lesley Scott11, Wendy Stevens11, Pamela Nabeta1, David Alland12, Karin Weyer13, Claudia M Denkinger1,14, Christopher Gilpin13.   

Abstract

Tests that can replace sputum smear microscopy have been identified as a top priority diagnostic need for tuberculosis by the World Health Organization. High-quality evidence on diagnostic accuracy for tests that may meet this need is an essential requirement to inform decisions about policy and scale-up. However, test accuracy studies are often of low and inconsistent quality and poorly reported, leading to uncertainty about true test performance. Here we provide guidance for the design of diagnostic test accuracy studies of sputum smear-replacement tests. Such studies should have a cross-sectional or cohort design, enrolling either a consecutive series or a random sample of patients who require evaluation for tuberculosis. Adults with respiratory symptoms are the target population. The reference standard should at a minimum be a single, automated, liquid culture, but additional cultures, follow-up, clinical case definition, and specific measures to understand discordant results should also be included. Inclusion of smear microscopy and Xpert MTB/RIF (or MTB/RIF Ultra) as comparators is critical to allow broader comparability and generalizability of results, because disease spectrum can vary between studies and affects relative test performance. Given the complex nature of sputum (the primary specimen type used for pulmonary TB), careful design and reporting of the specimen flow is essential. Test characteristics other than accuracy (such as feasibility, implementation considerations, and data on impact on patient, population and health systems outcomes) are also important aspects.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  WHO End TB strategy; diagnostics; study design guidance; target product profiles; tuberculosis

Mesh:

Substances:

Year:  2019        PMID: 31593597      PMCID: PMC6782025          DOI: 10.1093/infdis/jiz258

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  31 in total

1.  Spectrum bias or spectrum effect? Subgroup variation in diagnostic test evaluation.

Authors:  Stephanie A Mulherin; William C Miller
Journal:  Ann Intern Med       Date:  2002-10-01       Impact factor: 25.391

2.  Evaluation of processing methods to equitably aliquot sputa for mycobacterial testing.

Authors:  David Jamil Hadad; Carlos Gustavo Vieira Morais; Solange A Vinhas; Kevin P Fennelly; Reynaldo Dietze; Cristina Paula Nascimento; Moises Palaci
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

3.  The impact of new tuberculosis diagnostics on transmission: why context matters.

Authors:  Hsien-Ho Lin; David Dowdy; Christopher Dye; Megan Murray; Ted Cohen
Journal:  Bull World Health Organ       Date:  2012-07-16       Impact factor: 9.408

Review 4.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2014-01-21

5.  Isolation of tubercle bacilli from needle biopsy specimens of parietal pleura.

Authors:  L Scharer; J H McClement
Journal:  Am Rev Respir Dis       Date:  1968-03

6.  Which attributes within target product profiles for tuberculosis diagnostics are the most important to focus on?

Authors:  T Adepoyibi; L Lilis; H Greb; D Boyle
Journal:  Int J Tuberc Lung Dis       Date:  2018-04-01       Impact factor: 2.373

Review 7.  Pre-treatment loss to follow-up in tuberculosis patients in low- and lower-middle-income countries and high-burden countries: a systematic review and meta-analysis.

Authors:  Peter MacPherson; Rein M G J Houben; Judith R Glynn; Elizabeth L Corbett; Katharina Kranzer
Journal:  Bull World Health Organ       Date:  2013-11-22       Impact factor: 9.408

8.  Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis prevalence survey.

Authors:  Susan E Dorman; Violet N Chihota; James J Lewis; Maunank Shah; David Clark; Alison D Grant; Gavin J Churchyard; Katherine L Fielding
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

Review 9.  Impact of Molecular Diagnostics for Tuberculosis on Patient-Important Outcomes: A Systematic Review of Study Methodologies.

Authors:  Samuel G Schumacher; Hojoon Sohn; Zhi Zhen Qin; Genevieve Gore; J Lucian Davis; Claudia M Denkinger; Madhukar Pai
Journal:  PLoS One       Date:  2016-03-08       Impact factor: 3.240

10.  Surrogate endpoints in global health research: still searching for killer apps and silver bullets?

Authors:  Madhukar Pai; Samuel G Schumacher; Seye Abimbola
Journal:  BMJ Glob Health       Date:  2018-03-08
View more
  8 in total

1.  Performance of the Roche cobas MTB Assay for the Molecular Diagnosis of Pulmonary Tuberculosis in a High HIV Burden Setting.

Authors:  Lesley Scott; Anura David; Lyndel Govender; Jan Furrer; Modiehi Rakgokong; Ziyaad Waja; Neil Martinson; Gabriel Eisenberg; Elizabeth Marlowe; Wendy Stevens
Journal:  J Mol Diagn       Date:  2020-08-01       Impact factor: 5.568

2.  Use of DosR and Rpf antigens from Mycobacterium tuberculosis to screen for latent and relapse tuberculosis infection in a tuberculosis endemic community of Huainan City.

Authors:  Lirong Mao; Lifa Xu; Xiaochun Wang; Jianpeng Du; Qishan Sun; Zilun Shi; Jian Wang; Yingru Xing; Yixing Su; Ying Xu; Zhiyang Qi; Lu Xia; Jilei Ma; Jingyan Zhang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-05-25       Impact factor: 3.267

3.  Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid.

Authors:  Margaretha de Vos; Lesley Scott; Anura David; Andre Trollip; Harald Hoffmann; Sophia Georghiou; Sergio Carmona; Morten Ruhwald; Wendy Stevens; Claudia M Denkinger; Samuel G Schumacher
Journal:  J Clin Microbiol       Date:  2021-02-18       Impact factor: 5.948

4.  Validation of Differentially Expressed Immune Biomarkers in Latent and Active Tuberculosis by Real-Time PCR.

Authors:  Prem Perumal; Mohamed Bilal Abdullatif; Harriet N Garlant; Isobella Honeyborne; Marc Lipman; Timothy D McHugh; Jo Southern; Ronan Breen; George Santis; Kalaiarasan Ellappan; Saka Vinod Kumar; Harish Belgode; Ibrahim Abubakar; Sanjeev Sinha; Seshadri S Vasan; Noyal Joseph; Karen E Kempsell
Journal:  Front Immunol       Date:  2021-03-16       Impact factor: 7.561

5.  Asia emerges as a hotbed of diagnostic innovations for tuberculosis.

Authors:  Jacob Bigio; Wayne van Gemert; Brian Kaiser; Brenda Waning; Madhukar Pai
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2021-08-25

6.  Diagnostic Accuracy of the Truenat MTB Plus Assay and Comparison with the Xpert MTB/RIF Assay to Detect Tuberculosis among Hospital Outpatients in Cameroon.

Authors:  Yannick Russel Ngangue; Cyrille Mbuli; Angela Neh; Emmanuel Nshom; Armand Koudjou; Dennis Palmer; Norah Nyah Ndi; Zhi Zhen Qin; Jacob Creswell; Vincent Mbassa; Comfort Vuchas; Melissa Sander
Journal:  J Clin Microbiol       Date:  2022-07-21       Impact factor: 11.677

7.  Screening tests for active pulmonary tuberculosis in children.

Authors:  Bryan Vonasek; Tara Ness; Yemisi Takwoingi; Alexander W Kay; Susanna S van Wyk; Lara Ouellette; Ben J Marais; Karen R Steingart; Anna M Mandalakas
Journal:  Cochrane Database Syst Rev       Date:  2021-06-28

8.  A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays.

Authors:  Adam Penn-Nicholson; Sivaramakrishnan N Gomathi; Cesar Ugarte-Gil; Abyot Meaza; Evelyn Lavu; Pranav Patel; Bandana Choudhury; Camilla Rodrigues; Sarabjit Chadha; Mubin Kazi; Aurélien Macé; Pamela Nabeta; Catharina Boehme; Raman R Gangakhedkar; Sanjay Sarin; Ephrem Tesfaye; Eduardo Gotuzzo; Philipp du Cros; Srikanth Tripathy; Morten Ruhwald; Manjula Singh; Claudia M Denkinger; Samuel G Schumacher
Journal:  Eur Respir J       Date:  2021-11-04       Impact factor: 33.795

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.